my community channel

Register to store your favourite programmes, receive schedule alerts, sign up for factsheets, participate in forums and much more...

What's On

Sat 22nd Nov 2008
F	07:00	Action
F	07:15	Your Sport
F	07:30	The Generous Gene
F	08:00	Charge
	09:00	The Street Where You Live

full schedule

Home

Your Charity Space

Squiffy's Space

This item viewed 661 times

Other entries by Squiffy:

Results 1 - 5 of 190

About Squiffy

Webmaster and Discussion Board Administrator for the Multiple Sclerosis Resource Centre. http...

more...

Update on Copaxone FORTE Trial in Multiple Sclerosis

Create new blog

Teva Pharmaceutical Industries Ltd. announced top-line results from a Phase III study designed to assess the efficacy, safety and tolerability of glatiramer acetate (GA) 40mg as compared to the approved COPAXONE® 20mg in the treatment of relapsing-remitting multiple sclerosis (RRMS).

The 40mg dose did not demonstrate increased efficacy in reducing the relapse rate; however, the higher dose maintained the favourable safety and tolerability profile of COPAXONE® 20mg...................

For the full report please go to MSRC: MS Research News : Drugs : Disease Modifying Drugs : Disease Modifying Drugs Ongoing Research : COPAXONE® Ongoing Rese

Comments

There are no comments currently....

You must login to leave comments...

Last Updated ( Thursday, 10 July 2008 )

back to Your Charity Space

donate

send us feedback